Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis

Exclusion Criteria

• •History of more than 4 mild or moderate spine fractures or any severe fracture
• •Abnormality of the spine or hip that would prohibit assessment of BMD
• •History of bone disorders other than postmenopausal osteoporosis or a diagnosis of cancer within the last 5 years
• •History of Cushing's disease, thyroid, parathyroid, or malabsorptive syndromes or any chronic or recurrent diseases or disturbances that would interfere with the interpretation of study data or compromise the safety of the patient
• •Prior treatment with parathyroid hormone, parathyroid hormone-related peptide-derived drugs, or bone anabolic steroids, including abaloparatide, teriparatide, or parathyroid hormone (1-84)
• •Prior treatment with intravenous (IV) bisphosphonates at any time or oral bisphosphonates within the past 3 years; fluoride or strontium within the past 5 years; treatment with corticosteroids within the past 12 months; or selective estrogen receptor modulators within the past 6 months (except hormone replacement therapy)
• •Prior treatment with an investigational drug or device within the past 90 days or 5 half-lives of the investigational drug, whichever is longer
• •History of nephrolithiasis or urolithiasis within the past 5 years or hereditary disorders predisposing to osteosarcoma